Clinical Trial Update: Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1 [Phase 1]

View source ↗

Summary

This Phase 1 trial reports tolerability and safety results for sublingual lobeline at 30, 45, and 60 mg in individuals with methamphetamine dependence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methamphetamine Dependence

Drugs mentioned

• Lobeline (lobeline)

Snippet

Sponsor: National Institute on Drug Abuse (NIDA) | Conditions: Methamphetamine Dependence | Phase 1 | Status: UNKNOWN